A Study of AS-101 in Patients With AIDS or AIDS Related Complex (ARC)
Status:
Completed
Trial end date:
1993-03-01
Target enrollment:
Participant gender:
Summary
To determine the toxic effects of AS-101 at various doses in patients with AIDS or AIDS
related complex. Also to determine the effect of various doses of AS-101 on immune functions
and the occurrence of infections in these patients. AIDS is a viral disease that is
characterized by a loss of some immune function and the development of frequent, eventually
fatal, infectious diseases. Although zidovudine (AZT) has prolonged survival in some patients
with AIDS, AZT is quite toxic and there is a need for more effective and less toxic drugs.
AS-101 is a synthetic organic compound containing the metal tellurium that is being tested
because in laboratory studies it improved immune functions.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)